Navigation Links
Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
Date:6/27/2012

Tucson, Ariz. (PRWEB) June 26, 2012

SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that U.S. News & World Report has named three pediatric centers that offer the SynCardia temporary Total Artificial Heart among the nation’s Top 10 “Best Children’s Hospitals” for Cardiology and Heart Surgery in its annual list. The Children’s Hospital of Philadelphia (CHOP) was ranked #2, Texas Children’s Hospital was ranked #3 and Cincinnati Children’s Hospital Medical Center was ranked #9.

In May 2011, Texas Children's became the first pediatric hospital in the world to implant the Total Artificial Heart. The patient, 17-year-old Jordan Merecka, was born with a "reversed" heart (dextrocardia) and his heart vessels backwards (corrected transposition of the great arteries). In August 2011, he became the first pediatric Total Artificial Heart patient to be discharged from the hospital using the Freedom® portable driver, the world’s first wearable power supply for the Total Artificial Heart. Jordan received his heart transplant on Oct. 20, 2011. This August, he will begin his first day of classes in the Maritime Systems Engineering program at Texas A&M.

“One of the most impressive things about the Total Artificial Heart is it can take the most ill patients who are in multi-system organ failure, reverse the process and recuperate these patients for whom other forms of mechanical therapy may fall short,” said Dr. David L.S. Morales, Jordan’s surgeon and the new chief of pediatric cardiothoracic surgery at Cincinnati Children’s. “The Total Artificial Heart has opened the flood gates in respect to the treatment possibilities for a quickly growing population of children in heart failure, including adolescents suffering from chronic rejection of their transplanted heart, end-stage heart failure accompanied by multiple congenital defects and a chronic failed Fontan circulation.”

In January 2012, CHOP became the first hospital to implant the Total Artificial Heart into a pediatric patient who was born with only one functional heart ventricle and was suffering from a failed Fontan procedure. The teenager was bridged to a transplant with the Total Artificial Heart in March 2012.

“Pediatric patients who have undergone multiple operations often have no surgical options remaining other than cardiac transplantation,” said Dr. J. William Gaynor, an attending cardiothoracic surgeon at CHOP. “When the SynCardia Total Artificial heart is compared to ventricular assist devices, there is simply no other device which offers the same improvement in cardiac output, the same flexibility for complex congenital heart disease and the same opportunity to improve the condition of these patients and their long-term survival.”

In March, Phoenix Children's Hospital bridged its first patient to transplant with the Total Artificial Heart. This marked three consecutive pediatric patients bridged to transplant with the Total Artificial Heart during a six-month period ending March 2012.

The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

CAUTION – The Freedom® portable driver is an investigational device, limited by United States law to investigational use.

Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on [LinkedIn

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 250 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

SynCardia Ranked #20 Among World's 50 Most Innovative Companies

In March 2011, Fast Company magazine ranked SynCardia #20 in its annual list of the "World's 50 Most Innovative Companies" for "giving mobility to artificial heart recipients." Weighing 13.5 pounds, SynCardia's Freedom® portable driver is the world's first wearable driver designed to power the Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

Read the full story at http://www.prweb.com/releases/2012/6/prweb9640285.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved  

Related biology technology :

1. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
2. Discovery Labs to Present AFECTAIR® Data at European Congress on Pediatric and Neonatal Ventilation
3. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
4. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
5. At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter
6. iBio, Inc. Prices $10 Million Public Offering
7. Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
8. Spherix Announces Registered Direct Offering of $1.15 Million
9. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
10. Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations
11. OncoSec Closes $7.75 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
(Date:10/12/2017)... ... 12, 2017 , ... DuPont Pioneer and recently formed CasZyme, ... into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. The goal ... editing across all applications. , Under the terms of the agreement, Pioneer will ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of ... trends in analytical testing are being attributed to new regulatory requirements for all ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... it will be hosting a Webinar titled, “Pathology is going digital. Is your ... on digital pathology adoption best practices and how Proscia improves lab economics and ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):